| Cystic Fibrosis

Symdeko vs Trikafta

Side-by-side clinical, coverage, and cost comparison for cystic fibrosis.

Deep comparison between: Symdeko vs Trikafta with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTrikafta has a higher rate of injection site reactions vs Symdeko based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Trikafta but not Symdeko, including UnitedHealthcare

Category

Symdeko

Trikafta

At A Glance

RouteOral

FrequencyTwice daily

ClassCFTR corrector/potentiator

RouteOral

FrequencyTwice daily

ClassCFTR modulator

Indications

Cystic Fibrosis

Cystic Fibrosis

Dosing

Cystic Fibrosis Adults and patients >=12 years, or patients 6 to <12 years weighing >=30 kg: tezacaftor 100 mg/ivacaftor 150 mg in the morning and ivacaftor 150 mg in the evening, approximately 12 hours apart, with fat-containing food; patients 6 to <12 years weighing <30 kg: tezacaftor 50 mg/ivacaftor 75 mg in the morning and ivacaftor 75 mg in the evening, approximately 12 hours apart, with fat-containing food. Dose adjustment required for moderate or severe hepatic impairment and for co-administration with CYP3A inhibitors.

Cystic Fibrosis Weight-based oral doses (granules for ages 2 to <6, tablets for ages 6+) taken as a morning elexacaftor/tezacaftor/ivacaftor combination dose plus an evening ivacaftor dose approximately 12 hours apart with fat-containing food; dose reduced for moderate hepatic impairment and concomitant CYP3A inhibitors; not for use in severe hepatic impairment.

Contraindications

—

Drug Interactions

1565View drug interactions

935View drug interactions

Adverse Reactions

Most common (>=3%) headache, nausea, sinus congestion, dizziness

Serious transaminase elevations, hypersensitivity reactions including anaphylaxis, intracranial hypertension, neuropsychiatric events including suicidal thoughts and behaviors, cataracts, distal intestinal obstruction syndrome

Postmarketing anaphylaxis, rash, intracranial hypertension, anxiety, depression, suicidal ideation and behavior, insomnia

Most common (>=5%) Headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, alanine aminotransferase increased, nasal congestion, blood creatine phosphokinase increased, aspartate aminotransferase increased, rhinorrhea, rhinitis, influenza, sinusitis, blood bilirubin increased

Serious Drug-induced liver injury and liver failure, hypersensitivity reactions including anaphylaxis, intracranial hypertension, neuropsychiatric events including suicidal thoughts and behaviors, cataracts

Postmarketing Liver injury, fatal liver failure, liver transplantation, anaphylaxis, angioedema, intracranial hypertension, anxiety, depression, suicidal ideation and behavior, insomnia

Pharmacology

Tezacaftor/ivacaftor is a CFTR corrector/potentiator combination; tezacaftor facilitates cellular processing and trafficking of mutant CFTR protein (including F508del-CFTR) to the cell surface, while ivacaftor potentiates CFTR channel-open probability, together increasing the quantity and function of CFTR at the cell surface and resulting in increased chloride transport.

CFTR modulator triple combination; elexacaftor and tezacaftor are CFTR correctors that bind to different sites on the CFTR protein to facilitate cellular processing and trafficking of mutant CFTR (including F508del-CFTR) to the cell surface, while ivacaftor is a CFTR potentiator that enhances channel open probability at the cell surface, together resulting in increased CFTR quantity and function as measured by CFTR-mediated chloride transport and sweat chloride reduction.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Symdeko